17.00

1.39% -0.24

After Hours: 17.34 0.34 +2.00%

Viridian Therapeutics Inc (VRDN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Viridian Therapeutics Inc stock is traded at $17.00, with a volume of 1.49M. It is down -1.39% in the last 24 hours and up +23.82% over the past month. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Previous Close:

$17.24

Open:

$18

24h Volume:

1.49M

Relative Volume:

0.54

Market Cap:

$1.88B

Revenue:

$70.92M

Net Income/Loss:

$-342.21M

P/E Ratio:

-4.516

EPS:

-3.7644

Net Cash Flow:

$-304.30M

1W Performance:

+6.45%

1M Performance:

+23.82%

6M Performance:

-46.41%

1Y Performance:

+25.28%

1-Day Range:

$16.87

$18.00

1-Week Range:

$15.98

$18.20

52-Week Range:

$13.18

$34.29

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name

Viridian Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

617.272.4600

Address

221 CRESCENT STREET, WALTHAM

Employee

252

Twitter

Next Earnings Date

2026-05-05

Latest SEC Filings

VRDN's Discussions on Twitter

Compare VRDN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRDN Viridian Therapeutics Inc	17.00	1.90B	70.92M	-342.21M	-304.30M	-3.7644
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Reiterated	Wedbush	Outperform
Dec-03-25	Initiated	William Blair	Outperform
Nov-24-25	Initiated	Truist	Buy
Aug-25-25	Resumed	Jefferies	Buy
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy
Jun-11-24	Initiated	Wolfe Research	Outperform
Jun-06-24	Initiated	Goldman	Buy
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jun-14-23	Initiated	BTIG Research	Buy
Jun-14-23	Resumed	Credit Suisse	Outperform
May-30-23	Initiated	RBC Capital Mkts	Outperform
Apr-17-23	Initiated	Wells Fargo	Overweight
Mar-30-23	Initiated	Stifel	Buy
Dec-19-22	Initiated	Cowen	Outperform
Dec-19-22	Initiated	Needham	Buy
Dec-16-22	Initiated	Credit Suisse	Outperform
Dec-01-22	Initiated	H.C. Wainwright	Buy
Jun-23-22	Initiated	B. Riley Securities	Buy
Nov-18-21	Initiated	SVB Leerink	Outperform
Oct-12-21	Initiated	Evercore ISI	Outperform
Jan-25-21	Initiated	Ladenburg Thalmann	Buy

View All

Viridian Therapeutics Inc Stock (VRDN) Latest News

May 24, 2026

Does Viridian’s Upsized Note and Equity Offering Change The Bull Case For Viridian Therapeutics (VRDN)? - Sahm

May 24, 2026

May 23, 2026

Viridian Therapeutics prices upsized $350M concurrent stock and convertible notes offerings - MSN

May 23, 2026

May 21, 2026

Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M - Insider Monkey

May 21, 2026

Viridian Therapeutics releases topline phase 3 TED data elegrobart - Eyes On Eyecare

May 21, 2026

VRDN Stock Price, Quote & Chart | VIRIDIAN THERAPEUTICS INC (NASDAQ:VRDN) - ChartMill

May 21, 2026

May 20, 2026

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - AOL.com

May 20, 2026

May 19, 2026

Viridian Therapeutics launches $250M concurrent debt and equity offerings - MSN

May 19, 2026

PDUFA decision nears as Viridian Therapeutics (VRDN) advances TED pipeline and reports Q1 results - MSN

May 19, 2026

May 17, 2026

HighVista Strategies Sells 238,243 Shares of Viridian Therapeutics in Q1 2026News and Statistics - IndexBox

May 17, 2026

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - The Motley Fool

May 17, 2026

May 16, 2026

Why is Viridian Therapeutics stock sinking Monday? - MSN

May 16, 2026

VRDN: Wedbush Maintains Rating but Lowers Price Target | VRDN St - GuruFocus

May 16, 2026

Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $26 - Moomoo

May 16, 2026

Liquidity Mapping Around (VRDN) Price Events - Stock Traders Daily

May 16, 2026

VRDN Maintained by Evercore ISI Group -- Price Target Lowered to $26 - GuruFocus

May 16, 2026

May 15, 2026

Viridian Therapeutics Analyst Ratings and Price Targets | NASDAQ:VRDN - Benzinga

May 15, 2026